Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

6.3%

1 terminated/withdrawn out of 16 trials

Success Rate

93.3%

+6.8% vs industry average

Late-Stage Pipeline

50%

8 trials in Phase 3/4

Results Transparency

64%

9 of 14 completed trials have results

Key Signals

9 with results

Enrollment Performance

Analytics

Phase 3

7(58.3%)

Phase 1

3(25.0%)

Phase 4

1(8.3%)

Early Phase 1

1(8.3%)

12Total

Phase 3(7)

Phase 1(3)

Phase 4(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT03103542Phase 4Completed

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

Role: collaborator

NCT02546622Completed

ATHN 2: Factor Switching Study

Role: collaborator

NCT02502409Unknown

Natural History Study of Factor IX Treatment and Complications

Role: collaborator

NCT01181128Phase 3Completed

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Role: lead

NCT00716716Phase 1Completed

Phase I/IIa Study of FIXFc in Hemophilia B Patients

Role: lead

NCT01027364Phase 3Completed

Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B

Role: lead

NCT01440946Phase 3Completed

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B

Role: lead

NCT02083965Phase 1Completed

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Role: lead

NCT01454739Phase 3Completed

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

Role: lead

NCT01425723Phase 3Completed

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

Role: lead

NCT02502149Phase 3Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

Role: lead

NCT01027377Phase 1Completed

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Role: lead

NCT02392156Terminated

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

Role: lead

NCT01458106Phase 3Completed

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A

Role: lead

NCT02447627Completed

Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease

Role: lead

NCT03272568Early Phase 1Completed

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

Role: collaborator

All 16 trials loaded